Petlife Pharmaceuticals Inc
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concen… Read more
Petlife Pharmaceuticals Inc (PTLF) - Total Liabilities
Latest total liabilities as of February 2018: $1.98 Million USD
Based on the latest financial reports, Petlife Pharmaceuticals Inc (PTLF) has total liabilities worth $1.98 Million USD as of February 2018.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Petlife Pharmaceuticals Inc - Total Liabilities Trend (2006–2017)
This chart illustrates how Petlife Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Petlife Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Petlife Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ATVRockN
PINK:ATVK
|
USA | $3.12 Million |
Liability Composition Analysis (2006–2017)
This chart breaks down Petlife Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 252.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Petlife Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Petlife Pharmaceuticals Inc (2006–2017)
The table below shows the annual total liabilities of Petlife Pharmaceuticals Inc from 2006 to 2017.
| Year | Total Liabilities | Change |
|---|---|---|
| 2017-08-31 | $1.44 Million | -55.61% |
| 2016-08-31 | $3.24 Million | +773.36% |
| 2015-08-31 | $370.53K | -71.71% |
| 2012-08-31 | $1.31 Million | +182.85% |
| 2011-08-31 | $463.06K | -17.68% |
| 2010-08-31 | $562.52K | +23.43% |
| 2009-08-31 | $455.75K | -15.64% |
| 2008-08-31 | $540.24K | +80.44% |
| 2007-08-31 | $299.40K | +883.91% |
| 2006-08-31 | $30.43K | -- |